Norgine announces European Commission Marketing Authorisation for XOLREMDI® (mavorixafor), the first authorised treatment for patients with WHIM syndrome in the European Union

B Approval follows a positive opinion from the EMA’s Committee for Medicinal Products for Human Use (CHMP) EC approval marks a significant milestone for people…
posteditor
posteditor
Articles: 17424

Other News